Establishing a druggable target for KRAS driven cancers

For almost 30 years, the protein KRAS has been the "undruggable target" of cancer research.  Gene mutations in KRAS are responsible for 33% of all human cancers, including pancreatic, lung, and colon cancer.A new molecule identified by Dr. Bhairavi Tolani, an assistant professor at the University of California, San Francisco  upends conventional concepts of directly targeting the protein KRAS as a treatment strategy. Instead she suggests an alternative avenue for treatment of these deadliest cancers.Read her original research in Nature Biotechnology here: https://doi.org/10.1038/s41587-022-01386-z